

CHANGE - ANNOUNCEMENT OF APPOINTMENT::RE-DESIGNATION OF INTERIM CHIEF EXECUTIVE OFFICER AS CHIEF SCIENTIFIC OFFICER

Issuer & Securities

Issuer/ Manager

BIOLIDICS LIMITED

Securities

BIOLIDICS LIMITED - SGXE89830751 - 8YY

Stapled Security

No

Announcement Details

Announcement Title

Change - Announcement of Appointment

Date & Time of Broadcast

01-Sep-2021 18:12:10

Status

New

Announcement Sub Title

Re-designation of Interim Chief Executive Officer as Chief Scientific Officer

Announcement Reference

SG210901OTHRR4BQ

Submitted By (Co./ Ind. Name)

Yee Pinh Jeremy

Designation

Non-Executive Non-Independent Chairman

Description (Please provide a detailed description of the event in the box below)

Re-designation of Leong Man Chun from Interim Chief Executive Officer to Chief Scientific Officer of Biolidics Limited (the "Company").

This announcement has been prepared by the Company and has been reviewed by United Overseas Bank Limited (the "Sponsor") for compliance with Rules 226(2)(b) and 753(2) of the Singapore Exchange Securities Trading Limited (the "SGX-ST") Listing Manual Section B: Rules of Catalyst.

This announcement has not been examined or approved by the SGX-ST. The SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Mr. Lim Hoon Khiat, Director, Equity Capital Markets, who can be contacted at 80 Raffles Place, #03-03 UOB Plaza 1, Singapore 048624, telephone: +65 6533 9898.

Additional Details

Date Of Appointment

01/09/2021

Name Of Person

Leong Man Chun

Age

37

Country Of Principal Residence

Singapore

The Board's comments on this appointment (including rationale, selection criteria, and the search and nomination process)

Mr Leong Man Chun has been re-designated from Interim Chief Executive Officer ("CEO") to Chief Scientific Officer of the Company following the appointment of Mr Song Tang Yih as the CEO of the Company with effect from 1 September 2021.

The re-designation of Mr Leong Man Chun as Chief Scientific Officer was recommended by the Nominating Committee of the Company ("NC") after reviewing Mr Leong's professional and academic qualifications and working experience. The Board has approved the re-designation of Mr Leong as recommended by the NC.

Whether appointment is executive, and if so, the area of responsibility

Executive. Mr Leong Man Chun shall be responsible for managing the scientific, technological, and research operations of the Group.

Job Title (e.g. Lead ID, AC Chairman, AC Member etc.)

Chief Scientific Officer

Professional qualifications

1. Master in Business Administration, Manchester Business School
2. Doctor of Philosophy, National University of Singapore
3. Diploma d'ingenieur, Ecole Centrale Paris
4. Bachelor of Engineering (Bioengineering), National University of Singapore

Any relationship (including immediate family relationships) with any existing director, existing executive officer, the issuer and/ or substantial shareholder of the listed issuer or any of its principal subsidiaries

Nil

Conflict of interests (including any competing business)

Nil

Working experience and occupation(s) during the past 10 years

1. From 2020 to current: Interim CEO of Biolidics Limited
2. From 2019 to 2020: Chief Commercial Officer of Biolidics Limited
3. From 2018 to 2019: Innovation and Product Development Director of Clearbridge Health Limited
4. From 2017 to 2018: Diagnostic Services Manager of Clearbridge Health Limited
5. From 2016 to 2017: Clinical Projects Manager of Clearbridge Biomedics Pte. Ltd.
6. From 2013 to 2016: Application Scientist (Business Development) of Clearbridge Biomedics Pte. Ltd.
7. From 2007 to 2008: Market Research of Ecole Centrale Paris

Undertaking submitted to the listed issuer in the form of Appendix 7.7 (Listing Rule 704(7)) Or Appendix 7H (Catalist Rule 704(6))

Yes

Shareholding interest in the listed issuer and its subsidiaries?

Yes

Shareholding Details

792,000 shares

These fields are not applicable for announcements of appointments pursuant to Listing Rule 704 (9) or Catalist Rule 704 (8).

Past (for the last 5 years)

Nil

Present

Nil

(a) Whether at any time during the last 10 years, an application or a petition under any bankruptcy law of any jurisdiction was filed against him or against a partnership of which he was a partner at the time when he was a partner or at any time within 2 years from the date he ceased to be a partner?

No

(b) Whether at any time during the last 10 years, an application or a petition under any law of any jurisdiction was filed against an entity (not being a partnership) of which he was a director or an equivalent person or a key executive, at the time when he was a director or an equivalent person or a key executive of that entity or at any time within 2 years from the date he ceased to be a director or an equivalent person or a key executive of that entity, for the winding up or dissolution of that entity or, where that entity is the trustee of a business trust, that business trust, on the ground of insolvency?

No

(c) Whether there is any unsatisfied judgment against him?

No

(d) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving fraud or dishonesty which is punishable with imprisonment, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such purpose?

No

(e) Whether he has ever been convicted of any offence, in Singapore or elsewhere, involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or has been the subject of any criminal proceedings (including any pending criminal proceedings of which he is aware) for such breach?

No

(f) Whether at any time during the last 10 years, judgment has been entered against him in any civil proceedings in Singapore or elsewhere involving a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, or a finding of fraud, misrepresentation or dishonesty on his part, or he has been the subject of any civil proceedings (including any pending civil proceedings of which he is aware) involving an allegation of fraud, misrepresentation or dishonesty on his part?

No

(g) Whether he has ever been convicted in Singapore or elsewhere of any offence in connection with the formation or management of any entity or business trust?

No

(h) Whether he has ever been disqualified from acting as a director or an equivalent person of any entity (including the trustee of a business trust), or from taking part directly or indirectly in the management of any entity or business trust?

No

(i) Whether he has ever been the subject of any order, judgment or ruling of any court, tribunal or governmental body, permanently or temporarily enjoining him from engaging in any type of business practice or activity?

No

(j) Whether he has ever, to his knowledge, been concerned with the management or conduct, in Singapore or elsewhere, of the affairs of :-

(i) any corporation which has been investigated for a breach of any law or regulatory requirement governing corporations in Singapore or elsewhere; or

No

(ii) any entity (not being a corporation) which has been investigated for a breach of any law or regulatory requirement governing such entities in Singapore or elsewhere; or

No

(iii) any business trust which has been investigated for a breach of any law or regulatory requirement governing business trusts in Singapore or elsewhere; or

No

(iv) any entity or business trust which has been investigated for a breach of any law or regulatory requirement that relates to the securities or futures industry in Singapore or elsewhere, in connection with any matter occurring or arising during that period when he was so concerned with the entity or business trust?

No

(k) Whether he has been the subject of any current or past investigation or disciplinary proceedings, or has been reprimanded or issued any warning, by the Monetary Authority of Singapore or any other regulatory authority, exchange, professional body or government agency, whether in Singapore or elsewhere?

No

Any prior experience as a director of an issuer listed on the Exchange?

No

If no, please state if the director has attended or will be attending training on the roles and responsibilities of a director of a listed issuer as prescribed by the Exchange

Not applicable.

Please provide details of relevant experience and the nominating committee's reasons for not requiring the director to undergo training as prescribed by the Exchange (if applicable)

Not applicable.
